□ 本报记者徐维庆通讯员周健 "中试完成后，成品推向市场的成功率可达九成。"近日，站在已建成的全省最大合成生物蛋白制造中试 平台前，江苏创健医疗科技股份有限公司董事长钱松对合成生物的未来激情满满。 中间性试验，即小型生产模拟试验，是产品大规模量产前必不可少的环节。合成生物的中试，对相关企 业产品加速投向未来市场有着决定性作用。创健医疗投资1.2亿元，耗时两年时间打造了华东地区最大 的合成生物蛋白制造中试平台，集成陶瓷膜过滤、超滤、纳滤等多套纯化设备，实现酵母、大肠杆菌等 微生物发酵工艺开发与放大，同时结合AI实现全智能化生物制造，采用西门子自动化控制系统精准控 制工艺参数，每年可完成100—200批次工艺验证。 目前，创健医疗的中试平台已经开始承载核酸四面体、重组胶原蛋白等前沿项目工艺验证；同时，北京 市昌平合成生物制造技术创新中心、江南大学等高校科研院所与创健医疗联手，在常州启用部分先期科 研成果的中试，完成后将在全国范围内推广新品。 创健医疗在合成生物领域加码中试战略布局，有着更深层次的考量。以治疗阿尔茨海默病为例，在新药 开发中，基于DNA折纸技术构建，由4条单链DNA通过碱基互补配对原则，自发组装形成 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Insights - The company achieved a revenue of 1.15 billion yuan in 2024, representing a year-over-year growth of 33%, and a net profit of 246 million yuan, up 27% year-over-year [4] - The first quarter of 2025 saw a revenue of 313 million yuan, a 24% increase year-over-year, and a net profit of 81 million yuan, reflecting a 52% year-over-year growth [6] - The successful launch of new production capacities for soluble dietary fiber and crystallized sugar is expected to drive sales and revenue growth [6] Financial Data and Profit Forecast - The company forecasts total revenue of 1.72 billion yuan for 2025, with a year-over-year growth rate of 49% [5] - The projected net profit for 2025 is 365 million yuan, indicating a year-over-year growth of 48.7% [5] - Earnings per share (EPS) are expected to be 1.13 yuan for 2025, with a price-to-earnings (PE) ratio of 19 [5] Investment Analysis - The company is positioned as a leading producer of health food additives in China, with significant growth potential from the upcoming approval of D-allohexose as a new food ingredient [6] - The report highlights the successful transformation towards high-end dietary fiber products, which has led to increased profitability [6] - The planned issuance of convertible bonds aims to raise up to 780 million yuan for new projects, including a health food raw material factory in Thailand [6]

截至2025年4月30日收盘，星湖科技(600866)报收于7.56元，下跌1.05%，换手率3.45%，成交量38.24万 手，成交额2.92亿元。 董秘最新回复 投资者： 去年请问出口美国收入多少？ 董秘： 尊敬的投资者，您好！在国际市场上，公司产品远销欧洲、东南亚、韩国等50多个国家与地 区，公司2024年度国外整体销售收入情况请详见公司于2025年4月22日在上海证券交易所披露的临2025- 011号《2024年度主要经营数据公告》。感谢您的关注！ 投资者： 请问，截止4月25日收盘，股东户数多少？ 董秘： 尊敬的投资者，您好！关于公司的股东户数请详见公司于2025年4月22日在上海证券交易所披露 的《2025年第一季度报告》，感谢您的关注！ 投资者： 董秘您好，根据美国对中国的最新关税政策，对公司影响有多大，是否可以进行成本转移， 公司对美国出口的营业收入占比有多少，未来对美业务规划如何。 董秘： 尊敬的投资者，您好！在国际市场上，公司产品远销欧洲、东南亚、韩国等50多个国家与地 区，目前美国对中国的关税政策不会对公司的生产经营产生重大影响。公司将密切关注国际经济环境及 相关政策的变化，积极研究和制 ...

Investment Rating - The report indicates a bullish outlook on the major fermentation industry in China, highlighting it as a trillion-level bio-economy with diverse application scenarios that will drive the industry's growth curve [3][4]. Core Insights - Fermentation technology is becoming a core application direction in synthetic biology due to its green production, cost advantages, and technological innovations. It utilizes microbial metabolism to achieve sustainable production, significantly reducing carbon emissions and energy consumption [3][4]. - The Chinese fermentation industry is experiencing rapid growth driven by policy support, expansion of the biopharmaceutical market, and technological breakthroughs. The biopharmaceutical market is projected to grow from 218.5 billion yuan in 2017 to 620.3 billion yuan in 2024, accounting for 32% of the pharmaceutical market [4][31]. - Future development of the Chinese fermentation industry requires overcoming technical bottlenecks and accelerating cross-sector application penetration, with a focus on transforming from a pharmaceutical-dominated market to a multi-sector collaborative approach [5][34]. Summary by Sections Industry Overview - The report provides a comprehensive analysis of the current state of the fermentation industry in China and globally, including product characteristics, technological trends, and competitive landscape [3][4]. Key Drivers - The fermentation industry in China is driven by multiple factors: - Policy support from the government, which includes the incorporation of biological manufacturing into the "14th Five-Year Plan" and the implementation of carbon tax policies [4]. - The biopharmaceutical market's rapid expansion, which directly stimulates the demand for fermentation capacity [4][31]. - Technological advancements such as AI-assisted strain design and high-throughput screening that address traditional fermentation challenges [4][5]. Challenges - The industry faces challenges such as limitations in product concentration and purity, difficulties in strain selection and cultivation, and high production costs. The current market is heavily focused on the medical field, which accounts for 80% of the applications, while emerging sectors like food and agriculture have lower technological maturity [5][34]. Market Potential - The fermentation market is expected to grow significantly, with projections indicating that the global and Chinese fermentation market sizes will exceed 160 billion yuan and 120 billion yuan respectively by 2030, with a compound annual growth rate (CAGR) of 42.5% from 2024 to 2030 [47][53]. Competitive Landscape - The fermentation market is characterized by a high concentration of leading enterprises in the midstream production and processing segment, with a focus on continuous R&D investment and capacity integration to build competitive advantages [34][38]. - Key players include both international firms with established market presence and Chinese companies that are rapidly advancing in technology and market coverage [39][41].

（原标题：瑞德林刘建：重病之后，开启全新人生） 由"云上天泉"冠名播出的《Hi，老板》，最新一期约到了瑞德林董事长刘建。38岁那年，他的事业因为 重病按下暂停键。病愈后，带着对生命的全新敬畏，刘建选择创业，用6年的时间，带领瑞德林穿越死 亡谷，让公司成为合成生物领域的佼佼者。 点击观看视频：瑞德林刘建：重病之后，开启全新人生 以下是我们的对话，更多内容请关注"证券时报"官方视频号、抖音号《Hi，老板》专辑。 凌晨5点钟：属于自己的思考时间 刘建：我天性比较乐观，对生死看得比较开。 于德江：已经到生死这个维度了吗？ 刘建：当然，那叫恶性癌症。 于德江：2002年在兰大毕业之后，就来到了深圳，在一家药企工作，一路也做到了高层，什么原因要毅 然决然地去辞职创业？ 刘建：其实我是喜欢挑战的人，在上市公司，我也负责过一个公司，我们当初花十多个亿，收了一家公 司。我做总经理来做投后管理，它的企业在西北。相对来说，管理比较落后，把这样的一个企业，融入 到这种相对来说节奏比较快、管理要求比较高的一个体系，其实难度很大，所以那时候压力也大、应酬 也多，加上作息不规律、睡眠的时间不够，所以后来到了2015年、2016年的时候就生 ...

Core Viewpoint - The article highlights the financial performance of Kasei Biotech in Q1 2025, showcasing significant growth in revenue and net profit, primarily driven by the sales of long-chain dicarboxylic acids [2][4]. Financial Performance - Kasei Biotech reported a revenue of 776 million yuan in Q1 2025, representing a year-on-year increase of 13.3% [2][3]. - The net profit attributable to shareholders reached 137 million yuan, up 30.1% compared to the same period last year [2][3]. - The net profit after deducting non-recurring gains was 135 million yuan, reflecting a 31.4% increase year-on-year [2][3]. - Research and development expenses amounted to 60.55 million yuan, marking a 35.21% increase from the previous year [2][3]. Product and Market Insights - The growth in net profit is attributed to the increased sales volume and gross profit from the series of long-chain dicarboxylic acids [4]. - Long-chain dicarboxylic acids (LCDA) are gaining traction in various applications, including the production of high-performance materials and pharmaceuticals [5]. - Kasei Biotech is positioned as a leading global supplier of bio-manufactured long-chain dicarboxylic acids, capitalizing on the market shift from traditional chemical methods to more sustainable production [5]. Capacity and Future Outlook - Kasei Biotech has a production capacity of 115,000 tons per year for bio-manufactured long-chain dicarboxylic acids and other related products [7]. - The company has successfully ramped up production of new products, such as dodecanedioic acid, contributing to significant revenue growth [6].

Group 1 - The core viewpoint of the news is that Angel Yeast will face a lock-up expiration of 2.765 million shares next week, with a market value of approximately 98.49 million yuan, accounting for 0.32% of the pre-expiration circulating market value [1] - The type of shares being unlocked is equity incentive restricted shares, with the expiration date set for May 7, 2025 [1] - The shareholders involved in this lock-up expiration include core technical personnel and management, with the largest portion being 2.7078 million shares held by core staff [1] Group 2 - Angel Yeast Co., Ltd. is located in Yichang, Hubei Province, and was founded in 1986, specializing in yeast and deep-processed products widely used in various fields [2] - The company has a total fermentation capacity of 400,000 tons, holding a 55% market share in China and over 18% globally, making it the second-largest yeast producer in the world [2] - Angel Yeast has established a national-level enterprise technology center and has been recognized with over 300 authorized invention patents, contributing to the formulation of all national and industry standards in the yeast sector [2]

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 4月26日，第三届中国（安徽）科交会专项活动——合成生物平台建设和科技招商专项活动在合肥举办。 在重大项目签约环节，合肥高新区管委会、芜湖三山经开区管委会等地方政府单位与上海凯赛生物、深圳华大基因等企业集中签约了"生物基复合材料新 能源结构件研发制造项目"等5项"双招双引"重点项目， 累计投资达11.8亿元 。 其中，芜湖市三山经开区与 福莱 明生物 签约" 重组胶原蛋白和类胶原蛋白产品研发产业化项目 "；合肥市庐阳区与 华大基因 农业 签约" 华大生物农业 应用研究院建设和科技成果产业化项目 "； 安徽科宝生物 与中科院合肥物质研究院合作签约" 名贵中药材体培牛黄及其关键原料胆红素生物制造产业化 核心技术攻关 "项目，合肥高新区与 凯赛生物 签约" 生物基复合材料新能源结构件研发制造项目 "。 此外，由中国科学技术大学副校长周丛照、安徽师范大学常务副校长熊宇杰等专家学者发起的 安徽省合成生物学会 （筹）组建启动仪式也在当天举行。 资料来源： 添加微信请备注 ...

Core Viewpoint - The company reported a slight decline in revenue and net profit for Q1 2025, primarily due to high base effects and weakened demand in the large infusion segment, but maintains a positive outlook for steady profit growth in 2025 driven by product upgrades and new market explorations [1][2]. Group 1: Financial Performance - Q1 2025 revenue reached 3.079 billion yuan, a year-over-year decrease of 2.10%, with net profit attributable to shareholders at 507 million yuan, down 1.26% year-over-year [1]. - The large infusion segment saw a revenue decline of 16% year-over-year, totaling 770 million yuan, attributed to high base effects and seasonal demand fluctuations [1]. - Non-infusion segment revenue for Q1 2025 was 2.28 billion yuan, reflecting a year-over-year increase of 3.35%, driven by growth in gynecology and oncology specialties [2]. Group 2: Segment Analysis - The large infusion segment is expected to stabilize in sales volume, with ongoing upgrades in packaging and production efficiency to maintain profit levels despite revenue declines [1]. - The non-infusion segment's growth is supported by steady performance in chronic disease treatments and strong sales in specialty areas, particularly gynecology and oncology [2]. - The raw materials segment experienced an 8.7% year-over-year revenue decline, but is anticipated to recover due to new product introductions and improved sales volumes [2]. Group 3: Growth Potential - The company has established eight core technology platforms and is advancing over 20 key projects, indicating a robust pipeline for future growth [2]. - Expansion into e-commerce and OTC channels is expected to contribute to a targeted revenue growth of 10% in 2025 [2]. - New product launches, including innovative drugs for diabetes and antiviral treatments, are projected to drive revenue growth, supported by a strong sales team [2]. Group 4: Profit Forecast and Valuation - The company forecasts EPS of 1.69, 1.83, and 1.96 yuan for 2025, 2026, and 2027 respectively, with a target price of 27.04 yuan based on a 16x PE ratio for 2025 [3].

川宁生物（301301.SZ）2024 年年报及 2025 年一季报点评 Q1 业绩阶段性承压，看好全年改善、业绩维稳 2025 年 04 月 30 日 ➢ 事件：2025 年 4 月 22/29 日，公司公布 2024 年度及 2025 一季度报告。根据年 报，公司 24 年实现营业收入 57.6 亿元，同比增长 19.4%；实现归母净利润 14.0 亿元， 同比增长 48.9%；实现扣非归母净利润 14.0 亿元，同比增长 49.4%。根据 25Q1 报告， 公司 25Q1 实现营业收入 13.0 亿元，同比下滑 14.9%；实现归母净利润 2.9 亿元，同比 下滑 18.3%；实现扣非归母净利润 2.8 亿元，同比下滑 19.6%。 ➢ 24 年业绩拆分：24 年主营业务持续强劲，三大中间体产线同比维持快速增长。根 据年报，公司 24 年主营业务收入 54.0 亿元，同比增长 19.5%（其中医药中间体实现营 收 53.6 亿元，同比增长 20.5%）。中间体拆分来看，硫红收入 17.5 亿元，同比+12.7%、 青霉素类中间体收入 22.6 亿元，同比+17.0%、头孢类中间体收入 13.5 亿元，同 ...